Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
UiPath (NYSE:PATH) has launched agentic AI automation solutions focused on healthcare, targeting workflows such as medical records management and claims processing.
The company is partnering with firms including Genzeon, a vendor recognized by the Centers for Medicare & Medicaid Services (CMS), to help healthcare organizations adopt these tools.
UiPath recently acquired WorkFusion, adding further agentic AI capabilities that are expected to integrate into its broader automation platform.
UiPath built its reputation in robotic process automation, helping enterprises automate repetitive, rules based tasks. With healthcare specific agentic AI and the WorkFusion acquisition, the company is adding more context aware, task oriented agents that can handle complex, compliance heavy workflows. For investors, this development shifts the focus from general purpose automation toward deeper, vertical focused use cases.
Healthcare is a large, highly regulated sector where administrative burden and data fragmentation are ongoing challenges, especially around billing, coding, and documentation. UiPath’s new offerings, combined with a partner recognized by CMS, place the company closer to these friction points, which could influence adoption decisions over time. The way customers respond to these healthcare and agentic AI products will be important for assessing UiPath’s competitive position and long term relevance in automation software.
Stay updated on the most important news stories for UiPath by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on UiPath.
NYSE:PATH Earnings & Revenue Growth as at Mar 2026
We’ve flagged 1 risk for UiPath. See which could impact your investment.
✅ Price vs Analyst Target: At US$11.07 versus a consensus target of about US$15.93, the stock trades roughly 44% below analyst expectations.
✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading about 34.6% below fair value, which flags potential upside relative to its model.
❌ Recent Momentum: The 30 day return of about 11.7% decline shows recent sentiment has been weak despite the healthcare AI announcement.
There is only one way to know the right time to buy, sell or hold UiPath. Head to Simply Wall St’s company report for the latest analysis of UiPath’s Fair Value.
📊 The move into healthcare agentic AI and the WorkFusion acquisition broaden UiPath’s use cases into more complex, compliance heavy workflows.
📊 Watch how healthcare related deals, automation adoption, and any updates on integration of WorkFusion feed through to revenue and margins.
⚠️ Analysts currently expect earnings to decline by an average of 43.2% per year over the next 3 years, which could limit how much the market rewards new product launches.
For the full picture including more risks and rewards, check out the complete UiPath analysis. Alternatively, you can check out the community page for UiPath to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PATH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com